CAR-T Cell Therapy in China — Cost, Approved Products & Top Centers
China has nine NMPA-approved CAR-T products — including the world's first approved CAR-T for a solid tumor (2026) — delivered at leading hematology centers for roughly one-fifth of the US price, with full English-speaking coordination.
We are a patient-coordination service, not a hospital. We help you reach the right center and specialist; all diagnosis, treatment decisions and prescriptions are made by the treating physicians.
CAR-T therapy cost in China
A commercially approved CAR-T product in China costs roughly $138,000–$180,000 (about RMB 1.0–1.3 million) including hospitalization — against $500,000–$1,000,000 for the full pathway in the United States. Price depends on which of the nine approved products your disease calls for. That fee is paid directly to the hospital — we do not mark it up; our own service is a separate, per-case coordination fee, quoted after the hematology team reviews your records.
✅ Commonly included
- Pre-treatment evaluation, molecular and flow-cytometry tests
- Leukapheresis (T-cell collection)
- The approved CAR-T cell product
- Lymphodepletion chemotherapy and cell infusion
- Inpatient monitoring, standard ward care and discharge summary
– Usually not included
- Bridging therapy while cells are being manufactured
- Management of severe complications or intensive care, if needed
- Hospital stay beyond the standard length
- Later supportive treatment and long-term follow-up
- Flights, accommodation and daily living costs
China's NMPA-approved CAR-T products
China now has nine approved CAR-T therapies — more than most countries — covering lymphoma, leukemia, myeloma and, as of June 2026, the world's first approved CAR-T for a solid tumor. The treating team selects the product matched to your exact diagnosis.
| Product | Target | Approved for | List price |
|---|---|---|---|
| Yescarta (axi-cel) | CD19 | Large B-cell lymphoma | RMB 1.20M · ~$166,700 |
| Carteyva (relma-cel) | CD19 | Large B-cell & follicular & mantle-cell lymphoma | RMB 1.29M · ~$179,200 |
| Yuanruida (inati-cel) | CD19 | Adult B-ALL & large B-cell lymphoma | RMB 0.999M · ~$138,800 |
| Fucaso (eque-cel) | BCMA | Multiple myeloma | RMB 1.166M · ~$161,900 |
| Zevor-cel | BCMA | Multiple myeloma | RMB 1.15M · ~$159,700 |
| satri-cel (CT041) World first solid-tumor CAR-T | CLDN18.2 | Advanced gastric / GEJ cancer | RMB 0.99M · ~$137,500 |
Three further products are approved (including China's first pediatric B-ALL CAR-T and J&J's Carvykti); prices for some are not yet public. List prices as of 2026, paid to the hospital.
Leading CAR-T centers in China
We coordinate access to China's highest-volume CAR-T programs — from private international hospitals built for overseas patients to the public centers that pioneered CAR-T in China.
SinoUnited Hospital (Shanghai)
Bund-side private hospital with a dedicated international CAR-T center, a fast-tracked treatment package, English-speaking nursing and direct international-insurance billing. Works with all approved product makers.
Jiahui International Hospital
China's first wholly foreign-owned general hospital and a Massachusetts General Hospital partner; oncology center led by a US-trained oncologist, most CAR-T patients international.
Lu Daopei Hospital Group
China's most active CAR-T program by enrolled cases, with US-trained, English-speaking leadership — strongest for complex, relapsed and hard-to-treat disease.
Top public hematology centers
Tongji (Shanghai), the First Affiliated Hospital of Soochow University, the national Blood Diseases Hospital (Tianjin), Ruijin and Zhejiang University — among the highest-volume CAR-T programs in the country.
Conditions treated with CAR-T in China
Approved CAR-T indications span blood cancers and now one solid tumor. Eligibility always depends on your exact diagnosis, prior lines of treatment and current condition — confirmed by the hematology team after reviewing your records.
How long you'll be in China
CAR-T is delivered in two stages — T-cell collection, then manufacturing, infusion and close monitoring. Many centers let you collect cells on a short first trip, return home while they are manufactured, then come back for infusion.
Why patients choose China for CAR-T
Nine approved products
More approved CAR-T therapies than most countries — including the world's first for a solid tumor — so the team can match the product to your disease.
About one-fifth of US cost
$138,000–$180,000 including hospitalization, versus $500,000–$1,000,000 for the full pathway in the US.
No wait, no pre-authorization
Ample manufacturing capacity and no insurance pre-authorization delay — assessment can often begin within days.
End-to-end coordination
We handle the introduction, records translation, appointment booking, an English-speaking companion and your S2 medical visa paperwork.
From first message to treatment
Send your case
Share your diagnosis, pathology and treatment history. We reply the same business day (Beijing time).
Eligibility & quote
We confirm suitability and the right product with the center's team and return an itemized official quotation — no surprises.
Plan the trip
Appointment, S2 medical visa, English-speaking companion, transfers and accommodation near the hospital.
Treatment & follow-up
On-the-ground support through collection, infusion, monitoring and your discharge summary.
CAR-T in China: common questions
How much does CAR-T therapy cost in China?
Which CAR-T products are approved in China?
What conditions can CAR-T treat?
How long will I need to stay in China?
Do you provide the medical treatment yourselves?
Send your case for a free assessment
Share your diagnosis and records and we'll confirm CAR-T eligibility and the right product with the center's team, then return an official quotation — usually the same business day.
Prices shown are non-binding estimates as of 2026 and are always subject to the treating hospital's official quotation. CAR-T therapy carries significant medical risks, including cytokine release syndrome and neurological effects; suitability and outcomes are determined solely by the treating physicians. This page is general information and does not constitute medical advice. See our Medical Disclaimer.
